ArticlePloS one2026
Respiratory syncytial virus burden among Ugandan adults aged ≥65 years: A 15-year sentinel surveillance study of prevalence, coinfections, and comorbidities (2010-2025).
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus is an important cause of acute respiratory illness in older adults, yet data from sub-Saharan Africa remain scarce. Better understanding of its prevalence, coinfections, seasonal patterns, and risk factors in older populations is essential for strengthening surveillance systems and informing prevention strategies in low-resource settings.
methodsWe conducted a retrospective cross-sectional study using Uganda's national influenza-like illness and severe acute respiratory infection sentinel surveillance data from December 2010 to January 2025. Adults aged ≥65 years with real-time-PCR results for respiratory syncytial virus, influenza A and B, and SARS-CoV-2 were included. Descriptive analyses summarized prevalence, clinical characteristics, and temporal trends. Poisson regression with robust variance estimated adjusted prevalence ratios for factors associated with infection and hospitalization.
resultsAmong 545 illness episodes (mean age 73.2 years; 54.1% female), the period prevalence of respiratory syncytial virus across 2010-2025 was 4.8% (95% CI 3.3-6.9), comparable to influenza A (4.2%) and lower than SARS-CoV-2 (6.4%). Most RSV cases were mono-infections (92.3%), with rare respiratory syncytial virus-influenza coinfections (0.4%) and no respiratory syncytial virus-SARS-CoV-2 coinfections. Asthma and pneumonia were independent predictors of infection. Hospitalization was strongly associated with asthma, pneumonia, and heart disease. Activity showed seasonal peaks in March and June, with a marked decline during 2020-2021 and resurgence thereafter.
conclusionsRSV is a consistent contributor to medically attended respiratory illness among older Ugandan adults, with prevalence similar to influenza A. Although strong associations with asthma and pneumonia were observed, asthma-related findings are based on few cases and should be considered hypothesis-generating. Seasonal clustering and post-pandemic resurgence support integrating respiratory syncytial virus into routine respiratory surveillance and inform the targeted introduction of preventive interventions, including vaccination, in low- and middle-income settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.